Yahoo Finance

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares. The firm expects a “relatively uneventful” FDA review process for RP1 in combination with Opdivo for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The clinical impact should readily bolster the approval case, the analyst tells investors in a research note.

Invest with Confidence:

• Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.

• Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on REPL:

• Replimune announces BLA acceptance, priority review for RP1

• Replimune announces RP2 development program advances

• Replimune management to meet with Jefferies

• Replimune price target raised to $19 from $16 at Jefferies

• Replimune 6.923M share Spot Secondary priced at $13.00